Generated by AI
LivaNova PLC is a global medical technology company focused on designing, developing, manufacturing, and marketing therapies and devices for cardiac and neurological care. LivaNova PLC’s current business is organized around cardiopulmonary products, neuromodulation therapies, and advanced circulatory support, serving hospitals, clinicians, and healthcare systems with equipment used in cardiac surgery, temporary life support, and treatment of conditions such as drug-resistant epilepsy and difficult-to-treat depression. The company also provides related services and support for its medical devices, making it an important supplier in specialized hospital care and life-sustaining treatment settings. Headquartered in London, England, LivaNova PLC operates across international markets and plays a role in delivering targeted medical technologies for complex clinical needs.
Website5220 Valiant Court
Gloucester, GL3 4FE
United Kingdom
The latest articles about LIVN.
The bull case for LivaNova: 2026 guidance calls for 9%-10% revenue growth and 14% adjusted EPS growth; OSA's 2027 launch could add upside. Click for more on LIVN stock.
Summary of May 6's posts. Generated by AI.
Summary of Apr 5's posts. Generated by AI.
LivaNova reported third quarter 2026 sales of US$393.1 million and net income of US$34.3 million, alongside nine month net income of US$165.2 million, while newly published CORE VNS data highlighted multi year seizure reduction and quality of life benefits in drug resistant epilepsy. The combination of stronger profitability and 36 month VNS Therapy outcomes, including a 76% median seizure reduction and 73% fewer seizure related hospitalizations, directly links LivaNova's earnings profile to...
Summary of Oct 12's posts. Generated by AI.
Summary of May 6's posts. Generated by AI.
Investors talking about LIVN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.